secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001725160-24-000106
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q1 cash $489M; multiple azenosertib data readouts H2 2024–2025
-----------------------------------------------------------------------

- Cash, equivalents & marketable securities $489.0M (incl $56.7M Immunome stock); projected runway to mid-2026.
- R&D expense $49.6M (up $1M YoY); G&A $15.7M (down $0.7M). Quarterly net loss not disclosed.
- Key milestones: Phase 1 osteosarcoma data at 2024 ASCO; DENALI (PROC) topline H1 2025; TETON (USC) topline H2 2025.
- Interim CFO Cam Gallagher appointed April 5, 2024; search for permanent CFO underway.
- Azenosertib development on track with partnerships (GSK, Pfizer); registration-enabling trial in PSOC planned for 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/0001725160-24-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000106/zntl-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer